EsoCap announces the Presentation of the ACESO Trial Design at the Congress of the EAACI

  • Presentation of the ACESO-Trial Design, a randomized, placebo-controlled, double-blind trial evaluating the efficacy, tolerability, and safety of a novel delivery system (ESO-101) for topical esophageal treatment.
  • ESO-101, EsoCap’s lead product in the unique drug delivery system for the upper gastrointestinal tract, consists of a capsule with a rolled, thin mucoadhesive film, loaded with the anti-inflammatory corticosteroid, mometasone furoate.
  • Topical-administrated drugs have demonstrated superiority compared with systemically acting ones, but methods to deposit active compounds must be developed and tested.

Read full news release PDF here

Read ACESO abstract submission PDF here